Recent Updates in the Role of Bispecifics in Multiple Myeloma: Highlights from ASH 2022 and Beyond : Episode 2
Treatment Approaches in Transplant-Eligible NDMM
Sandy Wong, MD, and Alexander Lesokhin, MD, discuss how they approach the treatment of transplant-eligible NDMM using the Dara-RVd regimen.
EP: 1.GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis
Now Viewing
EP: 2.Treatment Approaches in Transplant-Eligible NDMM
EP: 3.Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM
EP: 4.Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy
EP: 5.Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity
EP: 6.Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM
EP: 7.Comparing Quadruplet Combination Treatment Regimens in NDMM
EP: 8.Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM
EP: 9.Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM
EP: 10.IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM
Recent Videos
Related Content
Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice
Ishmael Applewhite, BSN, RN-BC, OCN;Leslie Bennett, MSN, RN;Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®
May 6th 2024Podcast
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
![“I don't think [the CRL] impacts how I look at the data that is publicly available and the approval chances long term for linvoseltamab and how we might use it in the future,” said Surbhi Sidana, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F8b007a323176820eb0754e84186341fe7ca44ae4-350x350.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“I don't think [the CRL] impacts how I look at the data that is publicly available and the approval chances long term for linvoseltamab and how we might use it in the future,” said Surbhi Sidana, MD.")
